



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/672,323	09/28/2000	Michael J. Banker	10662-2	7573

7590 01/07/2003

Paul H Ginsburg
Pfizer Inc
235 East 42nd Street
20th Floor
New York, NY 10017-5755

EXAMINER

KIM, SUN U

ART UNIT

PAPER NUMBER

1723

DATE MAILED: 01/07/2003

11

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No. 09/672,323	Applicant(s) Banker et al.	Examiner John Kim	Art Unit 1723	52
	<i>-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --</i>				
	Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE <u>3</u> MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.				
- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).					
Status					
1) <input checked="" type="checkbox"/> Responsive to communication(s) filed on <u>Dec 16, 2002</u>					
2a) <input type="checkbox"/> This action is FINAL . 2b) <input checked="" type="checkbox"/> This action is non-final.					
3) <input type="checkbox"/> Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.					
Disposition of Claims					
4) <input checked="" type="checkbox"/> Claim(s) <u>1-5, 7-17, and 39</u> is/are pending in the application.					
4a) Of the above, claim(s) _____ is/are withdrawn from consideration.					
5) <input checked="" type="checkbox"/> Claim(s) <u>39</u> is/are allowed.					
6) <input checked="" type="checkbox"/> Claim(s) <u>1-5, 7, 10-12, and 14</u> is/are rejected.					
7) <input checked="" type="checkbox"/> Claim(s) <u>8, 9, 13, and 15-17</u> is/are objected to.					
8) <input type="checkbox"/> Claims _____ are subject to restriction and/or election requirement.					
Application Papers					
9) <input type="checkbox"/> The specification is objected to by the Examiner.					
10) <input type="checkbox"/> The drawing(s) filed on _____ is/are a) <input type="checkbox"/> accepted or b) <input type="checkbox"/> objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
11) <input type="checkbox"/> The proposed drawing correction filed on _____ is: a) <input type="checkbox"/> approved b) <input type="checkbox"/> disapproved by the Examiner. If approved, corrected drawings are required in reply to this Office action.					
12) <input type="checkbox"/> The oath or declaration is objected to by the Examiner.					
Priority under 35 U.S.C. §§ 119 and 120					
13) <input type="checkbox"/> Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) <input type="checkbox"/> All b) <input type="checkbox"/> Some* c) <input type="checkbox"/> None of: 1. <input type="checkbox"/> Certified copies of the priority documents have been received. 2. <input type="checkbox"/> Certified copies of the priority documents have been received in Application No. _____. 3. <input type="checkbox"/> Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).					
*See the attached detailed Office action for a list of the certified copies not received.					
14) <input type="checkbox"/> Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e). a) <input type="checkbox"/> The translation of the foreign language provisional application has been received.					
15) <input type="checkbox"/> Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.					
Attachment(s)					
1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)		4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____			
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)		5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)			
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s). _____		6) <input type="checkbox"/> Other: _____			

Art Unit: 1723

1. The finality of the action mailed on 8/9/02 is withdrawn.
2. Claims 4-5 and 14-17 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Recitation of "said membrane" in claims 4-5 lack positive antecedent basis. Claims 14-17 are indefinite for failing to particularly point out which means is "said means" in claims 14-17. Is "said means" means for vertically separating the well or means for holding bars together?
3. Applicant is advised that should claim 1 be found allowable, claim 2 will be objected to under 37 CFR 1.75 as being a substantial duplicate thereof. When two claims in an application are duplicates or else are so close in content that they both cover the same thing, despite a slight difference in wording, it is proper after allowing one claim to object to the other as being a substantial duplicate of the allowed claim. See MPEP § 706.03(k). Claim 2 recites that the means for vertically separating the well include dialysis membranes since means for vertically separating the well is dialysis membranes as claimed in its scope in the specification and there are no other means for vertically separating the well in the specification. Furthermore, "include" is essentially the same as "comprises".
4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person

Art Unit: 1723

having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

5. Claims 1-5, 7, 10-12 and 14 are rejected under 35 U.S.C. 103(a) as being unpatentable over U.S. Patent No. 3,623,611 (hereinafter referred to as Riley et al) in view of Harvard/Amika Interaction Studies (Multi-Equilibrium Dialyzer) brochure (hereinafter referred to as Harvard brochure). Riley et al teach a microdialyzer comprising a body comprising two elastic sheets (16, 18) having a top surface with openings (26a, 26b) and a closed bottom surfaces and a membrane (20) sandwiched between two plastic sheets (16, 18) in vertical orientation perpendicular to a first plane and second plane inherently parallel to the first plane wherein clamps (22, 24) hold the elastic sheets together with backing plates (12, 14) wherein rigid plates (12, 14) and plastic sheets (16, 18) are usually made of materials which are fluid-impervious and nonreactive with the materials involved in the dialysis may be used (see figures 1-3; col. 1, line 36 - col. 2, line 30). Claims 1-5, 7, 10-12 and 14 essentially differ in reciting that the body of device comprises the material polytetrafluoroethylene or Teflon. Harvard brochure teaches that the dialysis cells are made of Teflon. It would have been obvious to a person of ordinary skill in the art to substitute Teflon for the materials making up the body (16, 18, 12, 14) of Riley et al since Teflon is one of materials which are fluid impervious and nonreactive with materials involved in the dialysis.

6. Claims 8-9, 13 and 15-17 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

7. Claim 39 is allowed.

Art Unit: 1723


8. Applicant's arguments with respect to claims 1-5, 7-17 and 39 have been considered but are moot in view of the new ground(s) of rejection.

9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to John Kim whose telephone number is (703) 308-2350. The examiner can normally be reached on weekdays from 7:00 AM - 3:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Wanda Walker, can be reached on (703) 308-0457. The fax phone number for official response after final action is (703) 872-9311, and the fax phone number for all other official faxes is (703) 872-9310.

When sending a draft amendment by fax, please mark the paper as "DRAFT"; otherwise, mark the paper "OFFICIAL". This will expedite the processing of the paper.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0651.


John Kim
Primary Examiner
Art Unit 1723

J. Kim
January 2, 2003